TaperCommunity
The Maudsley Deprescribing Guidelines represent a significant shift in how clinicians and patients think about stopping psychiatric medications. Published in 2022 by Dr. Mark Horowitz and Professor David Taylor, the guidelines draw on receptor occupancy research to explain why standard tapering schedules so often produce severe withdrawal symptoms. For people who have struggled to come off antidepressants, benzodiazepines, or antipsychotics, these guidelines offer something that was previously rare: a pharmacological rationale for going slower and smaller than most doctors recommend. Understanding the maudsley deprescribing guidelines can help you have a more informed conversation with your prescriber and build a safer exit plan.
The Maudsley Deprescribing Guidelines is a clinical reference book, co-authored by Dr. Mark Horowitz and Professor David Taylor, that provides evidence-based tapering protocols for a wide range of psychiatric drugs. The first edition focused primarily on antidepressants and benzodiazepines. A second edition expanded coverage to antipsychotics, mood stabilizers, and other psychotropic medications. The book is published by Wiley-Blackwell and is used by psychiatrists, general practitioners, and clinical pharmacists worldwide.
Before this resource existed, most prescribers worked from manufacturer dosing instructions that were designed for starting medications, not stopping them. Withdrawal guidelines, when they existed at all, tended to recommend brief tapers over a few weeks, regardless of how long a patient had been on the drug or at what dose. The Maudsley guidelines challenged this approach directly, arguing that the neuropharmacology of these drugs demands a fundamentally different stopping strategy.
What makes the guidelines clinically useful is their combination of theoretical grounding and practical dose tables. Horowitz and Taylor do not just argue for slower tapering in the abstract. They provide specific hyperbolic reduction schedules tied to receptor occupancy data, making it possible for clinicians and patients to implement the approach concretely. The maudsley deprescribing guidelines also include guidance on managing withdrawal symptoms, distinguishing relapse from withdrawal, and deciding when to pause or slow down a taper.
The pharmacological foundation of the Maudsley approach is the concept of receptor occupancy, which describes the relationship between drug dose and how much of a receptor type in the brain the drug is actually binding to. This relationship is not linear. It follows a hyperbolic curve.
For antidepressants like Lexapro (escitalopram) or Zoloft (sertraline), most of the receptor occupancy is achieved at relatively low doses. Moving from zero to 10 mg of escitalopram occupies roughly 80% of the target serotonin transporter sites. Moving from 10 mg to 20 mg adds only a few additional percentage points of receptor occupancy. This is why doubling the dose rarely doubles the effect, and it is also why the final steps of a taper can produce the most intense withdrawal: cutting from 10 mg to zero removes a large proportion of residual receptor occupancy all at once.
Horowitz and Taylor formalized this concept in a 2019 paper published in The Lancet Psychiatry, which argued that antidepressant withdrawal is underappreciated in severity and duration because standard tapering regimens fail to account for hyperbolic dose-effect relationships. Their recommendation, which became central to the Maudsley guidelines, is to reduce doses in proportionally smaller absolute steps as the dose gets lower, not in equal absolute steps as most protocols assume.
This approach means that someone tapering off Effexor (venlafaxine) might reduce by 5 mg increments in the higher dose range but by 1 mg increments, or even smaller, as they approach zero. The total duration of the taper extends considerably, but withdrawal severity is substantially reduced when the approach is followed correctly.
Hyperbolic tapering is the practical application of receptor occupancy science. Instead of reducing by a fixed percentage or fixed milligram amount at each step, the patient reduces in a way that causes an approximately equal change in receptor occupancy at each step. Because of the curved dose-occupancy relationship, this means the actual milligram reductions get smaller and smaller as the dose decreases.
For many patients, this requires dose forms that standard pharmacies do not stock. The guidelines acknowledge this directly and discuss options including liquid formulations, compounding pharmacies, and techniques like dissolving tablets in water to achieve precise micro-doses. This is one of the more challenging aspects of implementing the Maudsley approach in practice, since healthcare systems vary considerably in how readily they accommodate non-standard dosing.
The guidelines provide dose tapering tables for specific medications, specifying what 5%, 10%, or other percentage reductions look like in actual milligrams at different starting points. These tables serve as a practical scaffold for building an individualized tapering plan in consultation with a prescriber. The key word is individualized: Horowitz and Taylor consistently emphasize that there is no single correct taper speed, and that patients should adjust their pace based on their symptoms rather than adhering rigidly to a predetermined timeline.
The maudsley deprescribing guidelines also recommend a "hold" strategy when withdrawal symptoms become difficult: pausing at a stable dose until symptoms resolve before continuing to reduce. This is a significant departure from conventional practice, where patients are often encouraged to push through symptoms to stay on schedule.
The first edition of the Maudsley Deprescribing Guidelines focused primarily on antidepressants, including SSRIs (selective serotonin reuptake inhibitors) and SNRIs (serotonin-norepinephrine reuptake inhibitors), along with benzodiazepines and z-drugs. The second edition, published in 2024, substantially expanded coverage to include antipsychotics, mood stabilizers such as lithium and valproate, ADHD medications, and other psychotropics.
For antidepressants, the guidelines cover virtually every commonly prescribed agent, with individual dose tables and notes on each drug's specific pharmacological characteristics. Some antidepressants, like fluoxetine, have very long half-lives that affect how withdrawal symptoms manifest and how tapering should be approached. Others, like paroxetine and venlafaxine, are known for particularly intense discontinuation syndromes and receive detailed attention in the guidelines.
For benzodiazepines, the guidelines complement but do not replace the Ashton Manual, a widely cited patient resource created by Professor Heather Ashton at Newcastle University. The Maudsley guidelines bring a more recent pharmacological framework to the benzodiazepine tapering literature and provide updated dose tables.
Coverage of antipsychotics in the second edition is particularly valuable, since this class of medications had very limited deprescribing guidance available previously. Patients stopping medications used to treat psychosis face unique challenges, including the difficulty of distinguishing withdrawal from return of illness, and the Maudsley guidelines address these clinical nuances carefully.
The gap between standard prescribing practice and what the maudsley deprescribing guidelines recommend is substantial. Most guidelines from professional bodies and drug manufacturers suggest tapering antidepressants over two to four weeks. The Maudsley approach often involves tapers lasting months to years for patients on moderate to high doses or for those who have been on medication for a long time.
Standard tapering advice also tends to be expressed as "reduce by half, then stop." This approach does not account for receptor occupancy, meaning the final step, going from half dose to zero, can produce the worst withdrawal symptoms of the entire process. Horowitz and Taylor have called this the "50-25-0" problem and argue it is a primary reason withdrawal is so frequently severe and misidentified as relapse.
Another key difference is how the guidelines treat symptom reports. Standard clinical responses to withdrawal complaints have often minimized them or attributed them to underlying illness. The Maudsley guidelines take withdrawal symptoms seriously as a pharmacological phenomenon, providing validated symptom scales and criteria for distinguishing withdrawal from relapse. This reframing has been important for patients who felt dismissed when reporting discontinuation difficulties.
The guidelines have also been influential in shifting how medical education approaches this topic. Several professional bodies have updated their guidance in the years since Horowitz and Taylor's 2019 Lancet Psychiatry paper, incorporating the concept of hyperbolic tapering into official recommendations for the first time.
The Maudsley Deprescribing Guidelines are written primarily as a clinical resource, meaning they are dense with pharmacological detail and designed for healthcare providers rather than lay readers. That said, many patients have read them directly or used the dose tables with the help of knowledgeable prescribers.
The most practical starting point for most patients is identifying which medication they are tapering and locating the relevant chapter or table. From there, the guidelines suggest a starting taper rate of 10% of the current dose every four weeks as a reasonable default, with the understanding that some people will tolerate faster reductions and others will need to go slower.
Symptom monitoring is built into the Maudsley approach. The guidelines recommend tracking symptoms systematically between dose reductions so that patients and clinicians have concrete data about what each reduction step produces. This makes it easier to calibrate pace and to recognize when a longer hold period is needed.
The maudsley deprescribing guidelines also address the psychological dimensions of tapering, including anxiety about stopping medication, fear of relapse, and the cognitive and emotional challenges that can arise during withdrawal. While this is not the primary focus of the text, the acknowledgment of these dimensions reflects a more complete picture of what deprescribing actually involves for patients.
The Maudsley Deprescribing Guidelines are an important resource, but they have limitations worth understanding. They are not clinical practice guidelines in the formal sense: they do not carry the endorsement of a national health authority and were not produced through a systematic review process with the same level of methodological transparency that formal guidelines require. Their recommendations, while grounded in pharmacological principles, rely on relatively limited direct trial evidence for the hyperbolic tapering approach itself.
The guidelines also cannot predict how any individual will respond to a given taper schedule. The dose tables are starting points, not prescriptions. Some patients taper successfully at rates faster than the guidelines suggest, while others find even very gradual reductions difficult. Individual variation in drug metabolism, receptor sensitivity, and life circumstances all affect the tapering experience in ways that no general resource can fully account for.
Access to the precise formulations required for hyperbolic tapering remains a practical barrier in many healthcare settings. Liquid formulations and compounding services are not universally available or covered by insurance, and not all prescribers are familiar with how to write prescriptions for them. The guidelines note these barriers but cannot resolve them on their own.
None of these limitations diminish the value of the resource. They simply reflect the reality that the guidelines are a tool for informing clinical decisions, not a substitute for individualized care.
The Maudsley Deprescribing Guidelines have given patients and clinicians a shared pharmacological language for what was previously a poorly documented and frequently minimized clinical problem. They do not make tapering easy, but they make it more understandable and more manageable when followed with appropriate support. If you are navigating a taper and want to connect with others doing the same, taper.community is a space built for exactly that.
This article is for informational purposes only and does not constitute medical advice. Always work with a qualified healthcare provider when making changes to your medication regimen.